Our study demonstrated that dapagliflozin might treat DN through regulating TGF-β signaling pathway, PPAR signaling pathway and chemokine signaling pathway by targeting 11 hub genes (SMAD9, PPARG, CD36, CYP4A12A, CYP4A12B,CASP3, H2-DMB2, MAPK1, MAPK3, C3, IL-10). The gene discussed is MAPK3; the disease is liver dysplastic nodule.